Press Release
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.
Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.
The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.
This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health.
Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.
About Vitiligo
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.
More About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
- The U.S. FDA approval information can be found on the Incyte official website, as follows:
- The EMA approval information can be found on the Incyte official website, as follows:
- The clinical studies information can be found on the Opzelura® official website, as follows:
https://www.opzelura.com/opzelura-prescribing-information
- China Insights Consultancy’s industrial report
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Tashkent, Uzbekistan – 16/03/2026 – (SeaPRwire) – FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally.
The problem it addresses
Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account.
FinHarbor’s approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves.
What changed in the new release
The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules.
Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed.
On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client’s internal policies and risk frameworks across different jurisdictions.
A recent deployment in four weeks
One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange.
The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner’s IBAN account infrastructure.
During the second week the team activated card issuing and configured the platform’s connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner.
The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps.
The final week was dedicated to integration testing, white-label interface customisation and the production launch.
According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation.
Industry perspective
“The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor.
“Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.”
Compliance and target users
The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API.
Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA.
FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure.
It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch.
About FinHarbor
FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond.
Learn more: www.finharbor.com
Social Links
LinkedIn: https://www.linkedin.com/company/finharbor/
Blog: https://www.finharbor.com/blog
Media contact
Brand: FinHarbor
Contact: Media team
Website: https://www.finharbor.com/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Meunier Brothers Real Estate Team Named Top 1 Percent Worldwide and No. 6 in Northern California for 2025 Sales Volume
The Meunier Brothers Real Estate Team, with Coldwell Banker Realty, has been recognized in the Top 1% of Coldwell Banker agents worldwide and ranked No. 6 in Northern California for 2025 sales volume production. The team also earned Coldwell Banker’s International Society of Excellence award for the 2025 award year.
The Meunier Brothers Real Estate Team, a Coldwell Banker Realty team serving Silicon Valley and Santa Clara County, has been recognized as a top-performing team for the 2025 award year. The team ranked No. 6 in Northern California for 2025 sales volume production and earned Coldwell Banker’s International Society of Excellence, an honor reserved for the top 1% of Coldwell Banker agents globally.
The International Society of Excellence award recognizes exceptional production and high-level client service, highlighting agents who reach significant milestones even in challenging market conditions. For the 2025 award year, the Meunier Brothers also achieved top regional ranking among Northern California teams.
“Our clients expect clarity, strategy, and strong execution from day one,” said Andy Meunier, Co-Founder and Team Lead. “This recognition reflects the work we put into pricing, preparation, marketing, and negotiation, and it reflects the trust our clients place in us.”
Ben Meunier, Co-Founder, added, “Markets shift. Expectations stay high. We focus on the details that move the outcome, from data-driven positioning to creating maximum exposure and negotiating every offer with the seller’s goals front and center.”
Known for a modern, proactive approach, the team’s process centers on three priorities: high-ROI home preparation guided by experienced contractors, maximum online exposure through professional media and targeted digital advertising, and disciplined offer strategy designed to secure the strongest terms and price.
About the Meunier Brothers Real Estate Team
The Meunier Brothers Real Estate Team is a third-generation Silicon Valley real estate team with Coldwell Banker Realty, led by Andy Meunier and Ben Meunier. The team serves clients across Silicon Valley, including Cupertino, Mountain View, Los Altos, Palo Alto, Santa Clara, San Jose, Sunnyvale, Campbell, Saratoga, Los Gatos, and more across Santa Clara County. The team is recognized for data-driven strategy, transparent communication, and high-touch client service.
Media Contact
Organization: Meunier Brothers Real Estate
Contact Person: Ben Meunier
Website: https://www.themeunierbrothers.com/
Email: Send Email
Address:19330 Stevens Creek Blvd
City: Cupertino
State: CA
Country:United States
Release id:41560
The post Meunier Brothers Real Estate Team Named Top 1 Percent Worldwide and No. 6 in Northern California for 2025 Sales Volume appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Lance A. Slatton, “The Senior Care Influencer,” named Official Brand Ambassador of the popular digital solution focused on unique needs of those with memory loss
Livonia, Michigan, United States, 16th Mar 2026 – Lance A. Slatton, widely known as “The Senior Care Influencer,” and founder and host of the popular All Home Care Matters, the nation’s leading caregiver-focused media platform, resource and voice in long-term care, was recently named as Official Brand Ambassador for My CareClock, the only digital solution focused on the unique needs of those with memory loss and those who care for them.
Slatton, respected throughout the health care and senior living community as an innovator, compassionate and forward-thinking leader, and passionate advocate for supporting health care providers, said he is proud to represent a company redefining how families and caregivers navigate senior care and memory support.
“Joining My CareClock as its Brand Ambassador is an honor that aligns perfectly with my mission to empower Alzheimer’s caregivers and families worldwide,” he said. “My CareClock is more than technology — it’s a lifeline for caregivers. I’m grateful to lend my voice and leadership for My CareClock. It allows me to continue my lifelong commitment to advancing compassionate, accessible senior care solutions.”
In January, Slatton took over the leadership role of AlzAuthors, the leading community of authors writing about Alzheimer’s and dementia. “As President of AlzAuthors and host of All Home Care Matters, I’m thrilled to be partnering with My CareClock,” he said. “As one of the top recognized healthcare and senior care influencers, I’m dedicated to raising awareness about tools like My CareClock that simplify and strengthen caregiving.”
My CareClock was founded by Maureen Mueller, whose passage into senior care living began like many, in her own home.
“When I began my caregiving journey in 2009, I felt very much alone, and at times, overwhelmed,” she said. “My mother-in-law was forgetting anything I told her on the phone, so I would have to go to her house and leave notes about doctor’s appointments. I was getting frantic calls early in the morning, while at work, and late at night because the notes had gotten misplaced.”
She knew there had to be a better way.
“I met with a software engineer friend, Stu Penrose, and asked him if he could help design something like a digital whiteboard that could be controlled by an app and could be updated in real time,” she said. “Within months we had a prototype in several homes, and we were getting great feedback. People were loving what came to be known as “My CareClock.”
The CareClock and App can be set up in minutes, and it’s very intuitive. Any family member and caregivers that are added to the “Care Team” can use the app to update the CareClock. Reminders and appointments can be scheduled for months ahead, but those reminders will only appear on the CareClock when it is time for them to be on the “Today” or “Tomorrow” screen.
Mueller is glad to welcome Slatton to the My CareClock family.
“The My CareClock team is very excited to be endorsed by Lance A. Slatton and All Home Care Matters,” she said. “This organization has worked tirelessly to help care-recipients and their care partners find the best resources to make their journey easier. With the help of Lance and AHCM, we are certain that more families will hear about and benefit from having “My CareClock” in their homes.”
For more information on My CareClock, visit mycareclock.com
About All Home Care Matters
All Home Care Matters, the nation’s leading voice in long-term care, currently has more than 116,000 YouTube subscribers and features almost 500 videos dedicated to helping provide resources to families as they face long-term care questions and issues for themselves and loved ones. AHCM and host Lance A. Slatton has received many prestigious awards since launching, including 2023 Recipient of the coveted YouTube Creator Award for surpassing 100,000 subscribers; 2024 Recipient of the Award in Excellence from the Academy of Interactive Visual Arts – The Communicator Award for Film & Video in Social Campaigns & Series in Healthcare; and 2024 Recipient of the GOLD w3 Award for Branded Entertainment in Health & Wellness for Dementia & Social Media. Official Website: www.allhomecarematters.com
About Lance A. Slatton
Widely known as “The Senior Care Influencer,” Lance A. Slatton, CSCM, is a seasoned professional with over 20 years experience in the healthcare industry and an award-winning visionary. His wealth of knowledge and experience, along with his innovative approach to providing care, have made him an indispensable asset in the healthcare field. He is the founder and host of the award-winning podcast & YouTube show All Home Care Matters and is a senior case manager at Enriched Life Home Care Services in Livonia, MI. He has been honored with many awards and distinctions over the years, including Top Influencer for Healthcare and Advocacy for 2024; recipient of the 2024 International Impact Book Award in the category of Caregiving; named 2026 Juror for the Academy of Interactive Visual Arts; named a 2025 Top Influencer for Healthcare & Advocacy; and in January 2026 became president of AlzAuthors, the leading community of authors writing about Alzheimer’s and dementia. He also is the author of “The Official Family Caregiver’s Guide” – available on Amazon.
Media Contact
Organization: All Home Care Matters
Contact Person: Lance A. Slatton
Website: Https://www.allhomecarematters.com
Email:
contact@allhomecarematters.com
Contact Number: +17347446477
City: Livonia
State: Michigan
Country:United States
Release id:42540
The post The Senior Care Influencer Lance A. Slatton partnering with My CareClock appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
FinHarbor Introduces Neobank Platform Designed to Go Live in Under 30 Days
Meunier Brothers Real Estate Team Named Top 1 Percent Worldwide and No. 6 in Northern California for 2025 Sales Volume
The Senior Care Influencer Lance A. Slatton partnering with My CareClock
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release3 days ago
ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders
-
Press Release4 days ago
Brian Hagerty Brings Proven Service Industry Leadership and Operational Expertise to Next Chapter
-
Press Release5 days ago
Post Oak Group Expands Its Capital Markets Practice Into European Markets
-
Press Release3 days ago
European Scientologists Expand Human Rights Education in Europe and Abroad
-
Press Release6 days ago
HumaTek Officially Lists $HUMC Token on PancakeSwap, Expanding Humanitarian Presence Across the Blockchain
-
Press Release4 days ago
Somos Martina Launches Period Uniform Program, Integrating Period Underwear into Colombian School Uniform System
-
Press Release4 days ago
A Mathematician’s Perspective: The MatrixFlow Model Behind Feather Exchange
-
Press Release5 days ago
Yijin Solution Optimizes Multi-Axis Manufacturing with Next-Generation 5-Axis CNC Machining